Milltrust To Launch Follow-On University Venture Fund

Milltrust, a London, UK-based investment organisation focused on ‘Sustainable Prosperity’ across both public and private capital markets, launched the British Innovation Fund II, along with a dedicated venture investment platform, Milltrust Ventures.

The fund will target high-impact, early-stage companies with links to UK University science and innovation.

British Innovation Fund II leverages deep connections with leading British research institutions, universities and NGOs, to go further in actively supporting promising start-ups with cutting-edge IP capable of disrupting a range of industries. A particular focus will be directed toward global food systems and health, which have been identified as key post-pandemic priorities, both for the UK and internationally.

The fund is already investing across three thematic verticals of Green Earth, Smart Proteins and Future Health, supporting UK science and innovation by providing timely capital and high value-add support to early-stage companies in the following fields: medical and diagnostic technologies, recycling and waste management, animal welfare and sustainable food production. 

Led by Alexander Kalis, Managing Partner, Milltrust Ventures has put together a dedicated team of investment managers and advisors with a number of notable appointments in recent months. The team includes:

  • Dr Bernard Ng, a medical and clinical affairs leader and former Chief Medical Officer at Bayer consumer division, who joins Milltrust as Chief Scientific Officer.
  • Hadyn Craig, an agriculture and food-systems specialist, who has been appointed to the board of Milltrust Ventures and brings expertise developed in previous roles as CEO of Capital Agri International, and as a senior consultant at AbacusBio Limited.
  • Harry Paul, who joins as venture partner, bringing 30 years of experience in both medical tech and agri-investment, including a former role in Milltrust’s farmland investments, sold to LPPI in 2022. He has also held senior roles at Boston Scientific and Roche earlier in his career. 

FinSMEs

28/03/2023